About JUVÉDERM® Ultra XC

Introduction
Before beginning your treatments, please review this important information.

Glossary of terms
Aesthetic—cosmetic, related to beauty
Anaphylaxis—severe allergic reaction
Bovine-based collagen—a dermal filler created from cow hides
Complimentary—free, at no cost
Cushioning agent—absorbs shock
Duration—length of time
Expressed a preference—subjects liked better
Gram-positive bacterial proteins—remnants of protein from the bacteria that produce the hyaluronic acid used in JUVÉDERM® Ultra XC
Hyaluronidase—an enzyme that breaks down hyaluronic acid
Hypertrophic scarring—a thick, hard scar that grows over the injured area
Inflammatory reaction—a localized response to injury, typically including pain, heat, redness, and swelling
Injection-site responses—side effects from treatment
Keloid formation—a thick, hard scar that grows outside the injured area
Nasolabial folds (NLFs)—the lines or wrinkles that run from the corners of the nose downward toward the corners of the mouth
NSAID—Nonsteroidal anti-inflammatory drug, such as aspirin or ibuprofen
Optimal—the best possible outcome
Pigmentation disorders—a lightening or darkening of an area of the skin
Topical—cream or ointment applied to a certain area of the skin and affecting only the area to which it is applied

What is it?
JUVÉDERM® Ultra XC injectable gel is a clear colorless hyaluronic acid gel that contains a small quantity of local anesthetic (lidocaine) and is injected directly into tissue to smooth wrinkles and folds, especially around the nose and mouth. Hyaluronic acid is a naturally occurring sugar found in the human body. The role of hyaluronic acid in the skin is to deliver nutrients, hydrate the skin by holding in water, and to act as a cushioning agent. The role of lidocaine is to reduce the pain associated with injections into the skin.

What does it do?
JUVÉDERM® Ultra XC temporarily adds volume to facial tissue and restores a smoother appearance to the face. The lidocaine in the gel improves the comfort of the injection.

How is it used?
JUVÉDERM® Ultra XC is injected into areas of facial tissue where moderate to severe facial wrinkles and folds occur. It temporarily adds volume to the skin and may give the appearance of a smoother surface.

What will it accomplish?
JUVÉDERM® Ultra XC injectable gel will help to smooth moderate to severe facial wrinkles and folds. Most patients need 1 treatment to achieve optimal wrinkle smoothing, and the results last about 9 months to 1 year.

What possible side effects?
Most side effects are mild or moderate in nature, and their duration is short lasting (7 days or less). The most common side effects include, but are not limited to, temporary injection-site reactions such as: redness, pain/tingling, firmness, swelling, lumps/bumps, bruising, itching, and discoloration.

As with all skin-injection procedures, there is a risk of infection.

Are there any reasons why I should not receive JUVÉDERM® Ultra XC (contraindications)?
Your physician will ask about your medical history to determine if you are an appropriate candidate for treatment. The product should not be used in patients who have:

• Severe allergies marked by a history of anaphylaxis or history or presence of multiple severe allergies
• A history of allergies to lidocaine or Gram-positive bacterial proteins

What should my physician warn me about?
The safety and effectiveness for the treatment of areas other than facial wrinkles and folds (such as lips) have not been established in controlled clinical studies.

What precautions should my physician advise me about?
The following are important treatment considerations for you to discuss with your physician and understand in order to help avoid unsatisfactory results and complications.

• Patients who are using substances that can prolong bleeding, such as aspirin or ibuprofen, as with any injection, may experience increased bruising or bleeding at injection site. You should inform your physician before treatment if you are using these types of substances
• If laser treatment, chemical peeling, or any other procedure based on active dermal response is considered after treatment with JUVÉDERM® Ultra XC, there is a possible risk of an inflammatory reaction at the treatment site
• JUVÉDERM® Ultra XC injectable gel should be used with caution in patients on immunosuppressive therapy, or therapy used to decrease the body’s immune response, as there may be an increased risk of infection
• The safety for use during pregnancy, in breast-feeding females, or in patients under 18 years has not been established
• The safety in patients with a history of excessive scarring (eg, hypertrophic scarring and keloid formations) and pigmentation disorders has not been studied

What did the clinical study show?
In the primary US clinical study to establish safety and effectiveness, 146 subjects were followed for 24 weeks after injection with JUVÉDERM® Ultra (without lidocaine) in 1 nasolabial fold (NLF) and ZYPLAST® dermal filler (bovine-based collagen) in the other. The percentage of subjects who reported common injection-site responses are presented in the table below.

Table 1—Injection-Site Side Effects (Nasolabial Folds) 1 N = 146

<table>
<thead>
<tr>
<th>Injection-Site Responses</th>
<th>JUVÉDERM® Ultra</th>
<th>ZYPLAST®</th>
</tr>
</thead>
<tbody>
<tr>
<td>Redness</td>
<td>136</td>
<td>93%</td>
</tr>
<tr>
<td>Pain/tenderness</td>
<td>131</td>
<td>90%</td>
</tr>
<tr>
<td>Firmness</td>
<td>129</td>
<td>88%</td>
</tr>
<tr>
<td>Swelling</td>
<td>125</td>
<td>86%</td>
</tr>
<tr>
<td>Lumps/bumps</td>
<td>115</td>
<td>79%</td>
</tr>
<tr>
<td>Bruising</td>
<td>86</td>
<td>59%</td>
</tr>
<tr>
<td>Itching</td>
<td>52</td>
<td>36%</td>
</tr>
<tr>
<td>Discoloration</td>
<td>48</td>
<td>33%</td>
</tr>
</tbody>
</table>

* Occurring in > 5% of subjects.
1 Number of subject NLFs with each specific injection-site response.

Injection-site responses were similar in duration and frequency for the JUVÉDERM® Ultra injectable gel and ZYPLAST® treated sides, were usually mild or moderate in severity, did not require intervention, and lasted 7 days or less.

JUVÉDERM® Ultra was found to provide a more persistent wrinkle correction than ZYPLAST® dermal filler over the 24-week course of the study. The percentage of subjects who maintained improvement with JUVÉDERM® Ultra at 24 weeks was 88% compared to 36% with ZYPLAST®. At the conclusion of the study, 129 (88%) of the 146 subjects expressed a preference for JUVÉDERM® Ultra injectable gel, while only 8 (5%) expressed a preference for ZYPLAST® and 9 (6%) had no preference.

Subjects who completed the 24-week study were invited to return for a complimentary repeat treatment. Subjects returned at their (or their physician’s) convenience. Of the 146 subjects, 116 (79%) returned for repeat treatment, on average at 9 months after their last injection. Forty-eight (48) subjects returned more than 36 weeks (9 months) after their last injection. The percentage of those subjects who had maintained improvement with JUVÉDERM® Ultra was 75%.

(Continued on reverse side.)
What did the clinical study show? (continued)

At multiple time points in the clinical study, subjects’ nasolabial folds were rated on a scale from 0 to 4.

Using this 5-point wrinkle assessment scale, the mean improvement since baseline was 1.9 at 2 weeks, 1.4 at 24 weeks, and 1.1 beyond 36 weeks after treatment.

### Table 2—Wrinkle Assessment Scale

<table>
<thead>
<tr>
<th>Improvement Since Baseline</th>
<th>Wiliness</th>
<th>Mild</th>
<th>Moderate</th>
<th>Severe</th>
<th>None</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>None</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Mild</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Moderate</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Severe</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Extreme</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

A subset of these subjects enrolled in a second study that followed subjects for 24-48 weeks after repeat treatment. Twenty-four (24) subjects were enrolled in the study. Twenty-three (23) were evaluated at 24 weeks (6 months) after repeat treatment with 67% maintaining improvement. Nine (9) subjects returned for evaluation 48 weeks (1 year) after repeat treatment: the percentage of those subjects who had maintained improvement with JUVÉDERM® Ultra injectable gel was 78%.

The mean improvement since baseline (ie, the average improvement from before treatment in patients using the wrinkle assessment scale listed in Table 2) was 1.4 at 24 weeks and 1.3 at 48 weeks after repeat treatment.

<table>
<thead>
<tr>
<th>Figure 2—Mean Improvement Scores, NLFs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Improvement Since Baseline (n = 24)</td>
</tr>
<tr>
<td>Week 2 (n = 142)</td>
</tr>
<tr>
<td>1.9</td>
</tr>
<tr>
<td>Week 12 (n = 130)</td>
</tr>
<tr>
<td>1.7</td>
</tr>
<tr>
<td>Week 24 (n = 139)</td>
</tr>
<tr>
<td>1.4</td>
</tr>
<tr>
<td>Week 25-28 (n = 60)</td>
</tr>
<tr>
<td>1.2</td>
</tr>
<tr>
<td>Weeks &gt; 36 (n = 48)</td>
</tr>
<tr>
<td>1.1</td>
</tr>
</tbody>
</table>

In another clinical study comparing JUVÉDERM® Ultra with and without lidocaine, 36 subjects received the product with lidocaine in 1 nasolabial fold and the product without lidocaine in the other. Subjects rated the level of pain during each injection. Pain was significantly less on the side that received JUVÉDERM® Ultra XC, and in comparing the 2 injections, 34 subjects (94%) found the lidocaine formulation to be less painful.

What side effects have been reported through voluntary postmarketing surveillance of JUVÉDERM® Ultra (without lidocaine) use in and outside of the United States?

The most commonly reported serious adverse events were swelling, redness, bruising, itching, firmness, and pain.

- Swelling and bruising generally occurred from immediately to 2 weeks postinjection. Treatment included amnica, NSAIDs, antihistamines, antibiotics, steroids, and hyaluronidase. In most cases, it went away within a day to one month
- Redness generally occurred from immediately to one week postinjection. Treatment included amnica, antihistamines, antibiotics, steroids, hyaluronidase, and laser treatment. In most cases, it went away within 1 to 4 weeks
- Itching generally occurred from immediately to one week postinjection. Treatment included NSAIDs, antihistamines, antibiotics, and steroids. In most cases, it went away within 3 days to 2 months
- Firmness generally occurred from one day to 2 months postinjection. Treatment included antihistamines, antibiotics, steroids, and hyaluronidase. In most cases, it went away within one week
- Pain generally occurred from immediately to 8 days postinjection. Treatment included NSAIDs, antihistamines, antibiotics, steroids, and hyaluronidase. In most cases, it went away within 1 to 6 weeks

Additionally, there have been reports of nodules, injection, allergic reaction, inflammation, abscess, deeper wrinkles, redness, and displacement.

- Nodules generally occurred from immediately to 2 weeks postinjection. Treatment included amnica, NSAIDs, antibiotics, steroids, and hyaluronidase. In most cases, it went away within 3 days to 1 month
- Inflammation generally occurred from immediately to 1 week postinjection. Treatment included NSAIDs, antibiotics, and steroids. In most cases, it went away within 6 to 10 days
- Allergic reaction generally occurred from immediately to 2 months postinjection. Treatment included antihistamines, antibiotics, steroids, and hyaluronidase. In most cases, it went away within 2 days to 4 months
- Abscess generally occurred from 2 days to 2 weeks postinjection. Treatment included antibiotics, steroids, and hyaluronidase. In most cases, it went away within 3 days to 2 months
- Deep wrinkle/scar generally occurred from immediately to 2 weeks postinjection. Treatment included antibiotics, steroids, and surgical correction of the scar. Deeper wrinkle/scar has been reported infrequently but more commonly after treatment in the glabellar region (the area between the eyebrows)
- Displacement (movement of product) generally occurred from immediately to 2 weeks postinjection. Treatment included antibiotics, steroids, hyaluronidase, and laser treatment

Other events that were reported included: blister, tingling sensation (paresthesia), bleeding at the injection site, skin rash, feeling of discomfort (malaise), headache, skin whitening (blanching), vision abnormalities, hives (urticaria), herpes simplex, dilated small blood vessels (telangiectasia), rapid swelling (angioedema), flu-like symptoms, nausea, vascular event, shortness of breath (dyspnea), rash (dermatitis), and granuloma at the injection site.

What is the discomfort during treatment like?

The treatment area may be injected with a topical anesthetic (cream placed directly on the injection site). The area around the injection site may be anesthetized using a local anesthetic before the injections. An anesthetic cream may be used to anesthetize the treatment area with a topical anesthetic (cream placed directly on the injection site) to further minimize discomfort.

What other treatments are available to me?

There are a variety of dermal fillers available in the United States that may be used for treatment. Aside from these, additional options for the correction of lines and wrinkles do exist, including facial creams, BOTOST™ Cosmetic (prabutinumumtoxina), chemical peels, and laser skin surface treatments. You may discuss these treatments with your physician.

When should I notify my physician?

Be sure to report to your physician (1) any redness and/or visible swelling that lasts for more than a few days and (2) any other symptoms that cause you concern. You may also contact the Allergan Product Support line at 1-877-345-5372.

For further questions and information, please call Allergan at 1-877-345-5372.

©2010 Allergan, Inc. * and ** marks owned by Allergan, Inc. JUVÉDERM® mark owned by Allergan Industrie, SAS. www.juvederm.com Re-order: LDDC-02930-02 104489